15 Key questions to be debated

1. How has the response to pandemic H1N1 influenza gone? How effective have the plans and preparations been in the face of a real pandemic threat?
   
   
2. What problems has the recent pandemic highlighted in terms of infrastructure, and how are they being addressed through renewed funding, procurement and licensing strategies?
   
   
3. What are the gaps in the development path to affordable vaccines for neglected diseases? What manufacturing technologies and policies are needed to enable vaccines to be distributed through WHO as well as being sold to the west?
   
   
4. From a commercial standpoint what are the pros and cons of cancer vaccines versus other treatment modalities? How is big pharma assessing opportunities in the field: What are they looking for next?
   
   
5. Quantifying the health economic value of vaccines for the 18+ population: What data is available on lifetime value and price? How might the evaluation of a new vaccine go beyond its direct impact, especially when looking at vaccines for adult / elderly populations?
   
   
6. What are the commercial promise and the latest clinical data for malaria and flavivirus vaccines, and emerging infectious diseases?
   
   
7. Are biotechs being bought for their platform technologies or their vaccine programs? How are the risks now being weighed up?
   
   
8. How do you position different vaccines based on immunogenicity and efficacy? How should the data be interpreted? Is it possible to translate higher response rates into longer lasting protection?
   
   
9. What is a healthy balance between egg and cell culture for long-term supply? If cell culture vaccine does not have a promotable advantage for sales in the face of higher costs, how do manufacturers justify it?
   
   
10. How are NGOs prioritizing and selecting investments in new vaccines? What is their characterization of need for the developing world?
    
    
11. Emerging competition: Analyzing the new international environment for vaccine manufacture and development - who are the new players and what are their strengths?
    
    
12. What impact are translational science and biomarkers having on regulatory concerns for licensing new adjuvants and delivery combinations?
    
    
13. How much synergy is there between prophylactic and therapeutic vaccines in terms of going after difficult, intractable viruses including HIV, HPV, Hep B and C?
    
    
14. Are we moving towards real recommendations and vaccine schedules for the adolescent vaccine sector? If so, for which diseases?
    
    
15. What are the pros and cons of different approaches to the universal influenza vaccine? How confident are they of finding correlates of protection of immunity? Could the universal influenza vaccine be used as a model for other viruses?
    

©Copyright Phacilitate Limited 2009

» Click here to review the combined programs for the Cell & Gene Therapy Forum and the Washington Vaccine Forum.

Click here to download the last three North American Vaccine Forum Main Announcements

Over 50 sponsors and exhibitors participated in 2009, with the floorplan sold out!

Click here to find out how your company can participate.